Familial Adenomatous Polyposis (FAP) Market Outlook

Thelansis’s “Familial Adenomatous Polyposis (FAP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Familial Adenomatous Polyposis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Familial Adenomatous Polyposis (FAP) Overview

Familial adenomatous polyposis (FAP) is a hereditary colorectal cancer syndrome caused by autosomal dominant germline mutations in the APC tumour suppressor gene, leading to constitutive Wnt/β-catenin pathway activation and progressive development of hundreds to thousands of colorectal adenomatous polyps — with virtually inevitable malignant transformation if left untreated. Attenuated FAP presents with fewer polyps and later onset, while classic FAP manifests in adolescence. Extracolonic manifestations are diagnostically and clinically significant, encompassing duodenal and periampullary adenomas, desmoid tumours — particularly post-surgical and in AFAP variants — gastric fundic gland polyps, osteomas, congenital hypertrophy of the retinal pigment epithelium, and thyroid malignancy. Diagnosis integrates clinical phenotyping, endoscopic assessment, and germline APC mutation confirmation, with cascade genetic testing of first-degree relatives essential. Prophylactic colectomy — ileal pouch-anal anastomosis or ileorectal anastomosis depending on rectal polyp burden — remains the cornerstone of colorectal cancer prevention, typically planned in late adolescence or early adulthood. Sulindac and celecoxib demonstrate polyp regression but are adjunctive rather than curative. Upper gastrointestinal surveillance addressing duodenal polyposis — stratified by Spigelman staging — is lifelong and critical given significant ampullary cancer risk. Prognosis is favourable with timely surgical intervention and surveillance adherence; genetic counselling, multidisciplinary coordination, and psychosocial support are integral to patient-centred, family-focused long-term management.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)